Thomas Fogarty
Co-Founder & Managing Director @ Emergent Medical Partners
San Jose, United States
Thomas Fogarty is a funding round investor at Emergent Medical Partners in San Jose focused on Medical and Health Care. Thomas Fogarty is the Co-Founder & Managing Director at Emergent Medical Partners.Dr. Thomas J. Fogarty is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and investor. He has been involved with a wide spectrum of innovations in business and technology, serving as founder/co-founder, and Chairman/boardmember of over 30 medical device companies, the majority based on devices designed and developed by Fogarty Engineering, Inc. Dr. Fogarty has published approximately 180 scientific articles and textbook chapters in fields of general and cardiovascular surgery, and is the author or co-author of more than 125 patents and patent applications. His patents include the “industry standard” Fogarty balloon embolectomy catheter (now owned by Edwards Lifesciences), and the widely used Aneurx Stent Graft (now owned by Medtronic). Dr. Fogarty is the recipient of countless awards and honors; most significantly, he is the recipient of the Presidential National Medal of Technology and Innovation 2014, Jacobson Innovation Award of the American College of Surgeons, the 2000 Lemelson-MIT prize for Invention and Innovation and was inducted into the Inventors Hall of Fame in December 2001. Dr. Fogarty is currently Clinical Professor of Surgery at Stanford University. Previously, he has held positions as President, Medical Staff at Stanford University Medical Center, and Director, Cardiovascular Surgery at Sequoia Medical Center. Dr. Fogarty was born in Cincinnati, Ohio and received his undergraduate education at Xavier University and his medical degree from the University of Cincinnati. He completed his residency at the University of Oregon. Dr. Fogarty was a founder and general partner of Three Arch Partners, and a general partner in five successive Three Arch venture funds.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Thomas Fogarty invests in
Stages Thomas Fogarty invests in
Countries Thomas Fogarty invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (38%)
- Health Care 3 (38%)
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
- Energy 1 (13%)
Stage
- Funding Round 2 (25%)
- Pre-Seed 1 (13%)
- Series B 1 (13%)
- Series D 1 (13%)
- Private Equity 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| WattCarbon develops decarbonization measurement and verification tools to track the carbon intensity of building energy use. The company was founded in 2021 with its headquarters in Lafayette, California. | $1.5M / Pre-Seed / Dec 14, 2021 | ||
| EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $30M / Private Equity / Aug 27, 2019 | ||
| EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $50M / Private Equity / Nov 14, 2017 | ||
| EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $20M / Apr 08, 2015 | ||
| Crux Biomedical, Inc., was formed in August 2004 by physicians Tom Fogarty and Frank Arko based upon their observations of the clinical limitations of current vena cava filters. | $8M / Series B / Jan 01, 2009 | ||
| Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure andcardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients.Satiety, Inc. was founded in 2000 through a collaboration of medical device incubators Thomas Fogarty Engineering and The Foundry, and is headquartered in Palo Alto, California. | $30M / Series D / Jul 19, 2007 | ||
Vivant Medical
|
Vivant Medical is an Information Technology company. | Jan 09, 2004 | |
| See all 8 investments → | |||
Co-Investors
Emergent Medical Partners is a California-based life sciences investment firm focused on medical device and healthcare companies. The firm was founded in 2006 and is headquartered in Portola Valley, California, United States.
Emergent Medical Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Thomas Fogarty
Co-Founder & Managing Director
|
|||
Allan May
Managing Director
|
|||
Bob Brownell
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Thomas Fogarty invest in?
Thomas Fogarty invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Thomas Fogarty?
Public channels for Thomas Fogarty include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thomas Fogarty last invest?
The most recent investment recorded for Thomas Fogarty closed in Dec 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
